A Bioactivated Lepidium latifolium Formulation Disrupts Mitochondrial Bioenergetics and Metabolic Adaptation in KRAS-Mutant Cancer Cells.

doi:10.3390/molecules31162779

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

A Bioactivated Lepidium latifolium Formulation Disrupts Mitochondrial Bioenergetics and Metabolic Adaptation in KRAS-Mutant Cancer Cells.

Molecules (Basel, Switzerland) - 10 Aug 2026

Conde-Rioll María, Cenigaonandia-Campillo Aiora, Sanz Silvia, Esteban José Antonio, Aguilera Oscar

Abstract excerpt

Pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC) are aggressive malignancies frequently driven by oncogenic Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations associated with metabolic reprogramming and resistance to apoptosis. In this study, we evaluated the antitumor and anti-inflammatory activity of a Lepidium latifolium L.-derived formulation (CTP) enriched in glucosinolate...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Apoptosis
Share to Cell Line, Tumor
Share to Energy Metabolism
Share to Glucosinolates

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mitochondria

Share to Plant Extracts

Share to Proto-Oncogene Proteins p21(ras)

Share to RAW 264.7 Cells

Source

Open in PubMed Open full text

Identifiers

PMID: 42653862
DOI: 10.3390/molecules31162779
PMCID: PMC13515240

Genes

KRAS
CETP

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.